DE1302648B - - Google Patents

Info

Publication number
DE1302648B
DE1302648B DENDAT1302648D DE1302648DB DE1302648B DE 1302648 B DE1302648 B DE 1302648B DE NDAT1302648 D DENDAT1302648 D DE NDAT1302648D DE 1302648D B DE1302648D B DE 1302648DB DE 1302648 B DE1302648 B DE 1302648B
Authority
DE
Germany
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DENDAT1302648D
Other languages
German (de)
Other versions
DE1302648U (cg-RX-API-DMAC10.html
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication of DE1302648B publication Critical patent/DE1302648B/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/30—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hydrocarbon radicals, substituted by hetero atoms, attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04D—NON-POSITIVE-DISPLACEMENT PUMPS
    • F04D29/00—Details, component parts, or accessories
    • F04D29/08—Sealings
    • F04D29/10—Shaft sealings
    • F04D29/12—Shaft sealings using sealing-rings
    • F04D29/126—Shaft sealings using sealing-rings especially adapted for liquid pumps
    • F04D29/128—Shaft sealings using sealing-rings especially adapted for liquid pumps with special means for adducting cooling or sealing fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mechanical Engineering (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Structures Of Non-Positive Displacement Pumps (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DENDAT1302648D 1960-09-27 Pending DE1302648B (cg-RX-API-DMAC10.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58632A US3102882A (en) 1960-09-27 1960-09-27 Derivatives of 3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide
GB991/61A GB902658A (en) 1960-09-27 1961-01-10 6-substituted (or unsubstituted) 2-alkyl-3-allylthiomethyl-7-sulphamyl-3,4-dihydrobenzothiadiazine dioxides and process for preparation

Publications (1)

Publication Number Publication Date
DE1302648B true DE1302648B (cg-RX-API-DMAC10.html)

Family

ID=26236340

Family Applications (2)

Application Number Title Priority Date Filing Date
DENDAT1302648D Pending DE1302648B (cg-RX-API-DMAC10.html) 1960-09-27
DE19611445121 Pending DE1445121A1 (de) 1960-09-27 1961-06-24 2-Methyl-3-allylmercaptomethyl-6-chlor-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyd und dessen pharmazeutisch geeignete Salze mit Basen und Verfahren zur Herstellung dieser Verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE19611445121 Pending DE1445121A1 (de) 1960-09-27 1961-06-24 2-Methyl-3-allylmercaptomethyl-6-chlor-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxyd und dessen pharmazeutisch geeignete Salze mit Basen und Verfahren zur Herstellung dieser Verbindungen

Country Status (6)

Country Link
US (1) US3102882A (cg-RX-API-DMAC10.html)
BE (1) BE606063A (cg-RX-API-DMAC10.html)
DE (2) DE1445121A1 (cg-RX-API-DMAC10.html)
ES (1) ES270748A1 (cg-RX-API-DMAC10.html)
FR (1) FR1426M (cg-RX-API-DMAC10.html)
GB (2) GB902658A (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265573A (en) * 1962-07-27 1966-08-09 Squibb & Sons Inc Benzothiadiazinesulfonamide-1, 1-dioxide composition
US3251837A (en) * 1962-09-14 1966-05-17 Pfizer & Co C Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
US4338435A (en) * 1981-06-01 1982-07-06 E. R. Squibb & Sons, Inc. Benzothiadiazines having diuretic activity
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
ATE331512T1 (de) 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
MEP27808A (en) 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
KR100668539B1 (ko) 2002-08-19 2007-01-16 화이자 프로덕츠 인크. 과증식성 질환에 대한 조합요법
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1606287B1 (en) 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
MA54261B1 (fr) 2019-01-18 2025-03-28 Astrazeneca Ab Inhibiteurs de pcsk9 et leurs procédés d'utilisation

Also Published As

Publication number Publication date
US3102882A (en) 1963-09-03
BE606063A (fr) 1962-01-12
ES270748A1 (es) 1961-12-16
GB902658A (en) 1962-08-09
FR1426M (fr) 1962-08-06
DE1445121A1 (de) 1968-11-28
GB905137A (en) 1962-09-05

Similar Documents

Publication Publication Date Title
DE1165129B (cg-RX-API-DMAC10.html)
DE1302648B (cg-RX-API-DMAC10.html)
BE601704A (cg-RX-API-DMAC10.html)
DE1243826C2 (cg-RX-API-DMAC10.html)
BE599788A (cg-RX-API-DMAC10.html)
FR1230848A (cg-RX-API-DMAC10.html)
BE602407A (cg-RX-API-DMAC10.html)
CS99283B5 (cg-RX-API-DMAC10.html)
SE218620C1 (cg-RX-API-DMAC10.html)
BE602865A (cg-RX-API-DMAC10.html)
BE604277A (cg-RX-API-DMAC10.html)
BE603541A (cg-RX-API-DMAC10.html)
BE603457A (cg-RX-API-DMAC10.html)
BE603418A (cg-RX-API-DMAC10.html)
BE603297A (cg-RX-API-DMAC10.html)
BE603201A (cg-RX-API-DMAC10.html)
BE603195A (cg-RX-API-DMAC10.html)
BE603082A (cg-RX-API-DMAC10.html)
BE603081A (cg-RX-API-DMAC10.html)
BE603030A (cg-RX-API-DMAC10.html)
BE602991A (cg-RX-API-DMAC10.html)
BE602940A (cg-RX-API-DMAC10.html)
BE602896A (cg-RX-API-DMAC10.html)
BE604612A (cg-RX-API-DMAC10.html)
BE603714A (cg-RX-API-DMAC10.html)